December 15, 2023 10:47 AM EST

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

AC Immune’s anti-pTau drug enters PhIIb: The Swiss biotech’s partner Johnson & Johnson launched the “potentially registration-enabling” study of ACI-35.030 in people with preclinical Alzheimer’s disease. AC Immune is now set to receive a milestone payout from J&J of CHF15 million ($17.3 million). The biotech also announced an offering of $50.1 million worth of shares, expected to close Tuesday. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Unlock this article instantly by becoming a free subscriber.

Moderna sticks to long-term strategy in first-quarter update, ends pact with Metagenomi

Exclusive: Spark co-founder launches new CNS gene therapy biotech with $54M

FDA asks for more data on Dupixent in COPD in move that could delay a decision

Novartis makes a $1B radiopharma deal, buying Mariana Oncology

As it cuts costs and pipeline, Bristol Myers hands back a cancer drug to Schrödinger

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

AC Im­mune's Alzheimer's drug heads to PhI­Ib; Cy­to­Dyn HIV drug on full hold; Syn­dax to raise $200M

News Reporter

Senior Reporter

Deputy Editor

Unlock this article instantly by becoming a free subscriber.

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M